BioCentury
ARTICLE | Financial News

Despite flurry of deals, follow-ons well short of 2018’s total

November 15, 2019 1:32 AM UTC
Updated on Nov 15, 2019 at 2:09 AM UTC

Four companies led by Reata raised over $600 million in follow-ons ahead of Thursday’s trading session, but even with the bolus of funding this year’s follow-ons lag last year’s pace.

A fifth company, Halozyme Therapeutics Inc. (NASDAQ:HALO), raised $400 million in a note deal to bring the fund-raising since Wednesday’s market close to more than $1 billion...